Here are five details.
1. For the quarter, TransEnterix reported $4.8 million in revenues compared to $1.9 million in revenue during the same period of 2017.
2. The company’s total net operating income and expenses were $5.4 million. In the first quarter of 2017, TransEnterix reported $16.5 million in total net operating income and expenses.
3. TransEnterix’s net loss in the first quarter was $900,000, as compared to $15.4 million in the same quarter of 2017.
4. Adjusted net loss in the first quarter topped $11.3 million or $0.06 per share. In the first quarter of 2017, the company’s adjusted new loss was $12.6 million or $0.11 per share.
5. TransEnterix sold two Senhance Systems in the first quarter, totally $3.5 million in sales. The company also filed an FDA submission to expand the use of the minimally invasive surgery system.
More articles on MIS:
University of Pennsylvania surgeons perform 1st-of-its-kind robotic spine surgery: 7 things to know
Medtronic launches new system for minimally invasive spine surgery: 5 things to know
NASS publishes positive coverage guidance for lumbar interspinous devices without fusion but with decompression
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
